The DNMT inhibitor decitabine is an FDA-approved effective chemotherapeutic agent for acute myelogenous leukaemia with anti-cancer effects also in head and neck cancer cells [153]. This evidence concerns the gene DNMT1 and acute myeloid leukemia.